GT200200195A - Tetrahidroquinolinas - Google Patents

Tetrahidroquinolinas

Info

Publication number
GT200200195A
GT200200195A GT200200195A GT200200195A GT200200195A GT 200200195 A GT200200195 A GT 200200195A GT 200200195 A GT200200195 A GT 200200195A GT 200200195 A GT200200195 A GT 200200195A GT 200200195 A GT200200195 A GT 200200195A
Authority
GT
Guatemala
Prior art keywords
tetrahydroquinolins
cholesterol
hypertrigliceridemias
hdlcolesterina
aterosclerosis
Prior art date
Application number
GT200200195A
Other languages
English (en)
Inventor
Heike Gielen
Siegfried Goldmann
Joerg Keldenich
Holger Paulsen
Carsten Schmeck
Stephan Siegel
Hilmar Bischoff
Martin Raabe
Delf Schmidt
Christiane Faeste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200200195A publication Critical patent/GT200200195A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A TETRAHIDROQUINOLINAS DE FORMULA GENERAL (I) EN DONDE A,B, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON INHIBIDORES ALTAMENTE EFICACES DE LAS PROTEINAS DE TRANSFERENCIA DE ESTER DE COLESTERINA (CETP) QUE POR LA INHIBICION ESTIMULAN EL TRANSPORTE INVERSO DE COLESTERINA EN LA SANGRE AUMENTANDO SIMULTANEAMENTE EL NIVEL DE HDLCOLESTERINA POR LO QUE SON DE UTILIDAD EN CUADROS DE HIPOLIPOPROTEINEMIA, DISLIPIDEMIAS, HIPERTRIGLICERIDEMIAS, ATEROSCLEROSIS.
GT200200195A 2001-10-01 2002-09-27 Tetrahidroquinolinas GT200200195A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10148436A DE10148436A1 (de) 2001-10-01 2001-10-01 Tetrahydrochinoline

Publications (1)

Publication Number Publication Date
GT200200195A true GT200200195A (es) 2003-08-22

Family

ID=7701007

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200195A GT200200195A (es) 2001-10-01 2002-09-27 Tetrahidroquinolinas

Country Status (12)

Country Link
US (1) US20050043341A1 (es)
EP (1) EP1434581A1 (es)
JP (1) JP2005508341A (es)
AR (1) AR036583A1 (es)
CA (1) CA2462030A1 (es)
DE (1) DE10148436A1 (es)
DO (1) DOP2002000457A (es)
GT (1) GT200200195A (es)
HN (1) HN2002000278A (es)
PE (1) PE20030604A1 (es)
UY (1) UY27458A1 (es)
WO (1) WO2003028727A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ546732A (en) 2003-09-26 2009-10-30 Japan Tobacco Inc Method of inhibiting remnant lipoprotein production
DE602004023100D1 (de) 2003-10-08 2009-10-22 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidemie
WO2005097805A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
MX2007007187A (es) * 2004-12-18 2007-08-14 Bayer Healthcare Ag Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol.
EP1828137B1 (de) * 2004-12-18 2012-04-25 Bayer Pharma Aktiengesellschaft 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
CN101096363B (zh) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
US20080145498A1 (en) * 2006-12-14 2008-06-19 Kraft Foods Holdings, Inc. Texture and shape control process for acidified food products
WO2009109549A1 (en) * 2008-03-05 2009-09-11 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
MX2012009149A (es) * 2010-02-19 2012-09-28 Boehringer Ingelheim Int Derivados de piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su preparacion.
JP5739426B2 (ja) 2010-07-09 2015-06-24 宇部興産株式会社 置換ピリジン化合物
AR087577A1 (es) 2011-08-17 2014-04-03 Boehringer Ingelheim Int Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparacion
EP2801574B1 (en) 2012-01-06 2016-07-27 Daiichi Sankyo Company, Limited Acid adduct salts of substituted pyridine compound as cholesteryl ester transfer protein (cetp) inhibitors
JP6742316B2 (ja) * 2014-09-09 2020-08-19 ベーリンガー インゲルハイム インターナショナル トレイディング （シャンハイ） カンパニー リミテッド スピロ［２．５］オクタン−５，７−ジオンおよびスピロ［３．５］ノナン−６，８−ジオンの調製のための新規なプロセス

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline

Also Published As

Publication number Publication date
PE20030604A1 (es) 2003-09-07
HN2002000278A (es) 2002-12-20
DE10148436A1 (de) 2003-04-17
JP2005508341A (ja) 2005-03-31
WO2003028727A9 (de) 2003-11-13
EP1434581A1 (de) 2004-07-07
US20050043341A1 (en) 2005-02-24
CA2462030A1 (en) 2003-04-10
UY27458A1 (es) 2003-04-30
DOP2002000457A (es) 2003-04-15
WO2003028727A1 (de) 2003-04-10
AR036583A1 (es) 2004-09-15

Similar Documents

Publication Publication Date Title
GT200200195A (es) Tetrahidroquinolinas
GT200200136A (es) Compuestos heterobiciclicos sustituidos con triamida
CY1108578T1 (el) Φαρμακευτικες συνθεσεις (κιτ) περιλαμβανοντας ενωσεις διϋδροπυριδινονης και εναν ανοσορυθμιστικο (ή εναν αντιφλεγμονωδη) παραγοντα και οι χρησεις αυτων
BR0209238A (pt) Compostos úteis como intermediários
ES2115237T3 (es) Fenil heterociclos como inhibidores de la ciclooxigenasa-2.
CR9465A (es) Compuestos mejorados farmacocineticamente
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
GT200200053A (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7
UY28280A1 (es) 2- hidroxi - 3- diaminoalcanos de benzamida
GT199900150A (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas.
NO20051469L (no) Immunstimulerende nukleinsyrer.
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
GT200200122A (es) Imidazotriazinas
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
CY1105915T1 (el) Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
CR9528A (es) Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
BR0211502A (pt) Derivados de ácido acético de indano e seu uso como agentes farmacêuticos, intermediários, e método de preparação
AR029775A1 (es) Derivados de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2-sustituidas, procedimiento para su preparacion, formas cristalinas de los mismos y metodo de tratamiento de la aterosclerosis que lo utiliza
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
GT200100148A (es) Derivados de 4-fenil-piridina.
BR0313969A (pt) Inibidores de oxitocina
TR199902703T2 (xx) Proteaz inhibit�rleri.